- Home
- FHN vs EXAS Comparison
FHN vs EXAS Comparison
Compare FHN & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHN
- EXAS
- Stock Information
- Founded
- FHN 1864
- EXAS 1995
- Country
- FHN United States
- EXAS United States
- Employees
- FHN N/A
- EXAS N/A
- Industry
- FHN Major Banks
- EXAS Medical Specialities
- Sector
- FHN Finance
- EXAS Health Care
- Exchange
- FHN Nasdaq
- EXAS Nasdaq
- Market Cap
- FHN 10.7B
- EXAS 9.9B
- IPO Year
- FHN N/A
- EXAS N/A
- Fundamental
- Price
- FHN $21.19
- EXAS $52.99
- Analyst Decision
- FHN Buy
- EXAS Strong Buy
- Analyst Count
- FHN 17
- EXAS 20
- Target Price
- FHN $23.09
- EXAS $70.26
- AVG Volume (30 Days)
- FHN 6.1M
- EXAS 2.9M
- Earning Date
- FHN 07-16-2025
- EXAS 08-06-2025
- Dividend Yield
- FHN 2.81%
- EXAS N/A
- EPS Growth
- FHN N/A
- EXAS N/A
- EPS
- FHN 1.44
- EXAS N/A
- Revenue
- FHN $3,043,000,000.00
- EXAS $2,828,128,000.00
- Revenue This Year
- FHN $11.18
- EXAS $14.61
- Revenue Next Year
- FHN $3.73
- EXAS $12.65
- P/E Ratio
- FHN $14.82
- EXAS N/A
- Revenue Growth
- FHN 3.43
- EXAS 11.57
- 52 Week Low
- FHN $14.34
- EXAS $39.97
- 52 Week High
- FHN $22.44
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- FHN 53.48
- EXAS 48.51
- Support Level
- FHN $21.67
- EXAS $51.37
- Resistance Level
- FHN $22.22
- EXAS $55.90
- Average True Range (ATR)
- FHN 0.43
- EXAS 2.37
- MACD
- FHN -0.01
- EXAS -0.00
- Stochastic Oscillator
- FHN 48.76
- EXAS 39.67
About FHN First Horizon Corporation
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The company's reportable segments are: Commercial, Consumer & Wealth, Wholesale, and Corporate. The majority of its revenue is generated from Commercial, Consumer & Wealth. The Commercial, Consumer & Wealth segment offers financial products and services, including traditional lending and deposit taking, to commercial and consumer clients in the southern USA and other selected markets.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.